Archives

Should You Invest in Ozempic Maker Novo Nordisk in 2026? – The Motley Fool

Should You Invest in Ozempic Maker Novo Nordisk in 2026?  The Motley Fool Weight-loss pill approval set to accelerate food industry product overhauls  Reuters Best Semaglutide Options for 2026: New Oral Wegovy Pill Approved by FDA as Patients Compare Injectable and Compounded Access Pathways  Yahoo Finance Weight-Loss Drugs Are Changing. Here’s What to Know  Bloomberg.com The FDA just approved […]

Muscle mommies want more protein — and brands are racing to feed them

Women, seeking muscle gains and weight loss, are driving innovation in the protein snack segment. Mohammed Saad/Anadolu via Getty Images Women, seeking muscle gains and weight loss, are increasing their protein intake in their diet. Popular protein-forward brands like Chomps and Wilde are leaning in to the female-driven demand. Keen interest from female buyers, who […]

JCM, Vol. 15, Pages 222: Clinical Outcomes Associated with the Use of a Family-Based Digital Support Program in Patients with Pharmacologic Treatment for Obesity

JCM, Vol. 15, Pages 222: Clinical Outcomes Associated with the Use of a Family-Based Digital Support Program in Patients with Pharmacologic Treatment for Obesity Journal of Clinical Medicine doi: 10.3390/jcm15010222 Authors: Antonio de Arriba Muñoz Oscar Eduardo Rodríguez-Montes Ana Rocío Conde-Moro María Teresa Garcia Castellanos José Andrés Martínez García Luis Fernández-Luque Background/Objectives: The Adhera® Caring […]

Ozempic isn’t about weight loss. It’s about food scarcity.

Alright, hear me out before you downvote me into oblivion. I’ve been thinking a lot about the sudden, aggressive push behind these GLP-1 drugs like Ozempic, Wegovy, etc. Yes, obesity is a real issue. Yes, these drugs help people. I’m not denying that. But I keep coming back to this question: Why this hard, this […]

$ISRG – Deciphering the Durability of a Surgical Revolution

$ISRG – Deciphering the Durability of a Surgical Revolution Intuitive Surgical, Inc. BATS:ISRG KalaGhazi Intuitive Surgical, Inc. (NASDAQ: ISRG) stands at a critical inflection point in its corporate narrative. The company’s third-quarter 2025 results, headlined by a robust 20% year-over-year growth in combined da Vinci and Ion procedures, have reignited a fundamental debate among investors: […]

Bear of the Day: Novo Nordisk (NVO)

Novo Nordisk (NVO) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human insulins. Based in Bagsværd, Denmark the company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity. Wegovy, […]

2 Top Growth Themes Beyond AI and How to Invest in Them

Quick Read The iShares Biotechnology ETF is up 30% year to date versus 17% for the S&P 500. IBM trades at 36.1x trailing P/E with a $283B market cap despite quantum computing advances. Market sentiment on AI stocks has shifted from overheated to doubtful as AI excitement fades. It sounds nuts, but SoFi is giving new […]

Should You Invest in Ozempic Maker Novo Nordisk in 2026?

Is there a more popular health trend right now than GLP-1 agonist obesity drugs such as Ozempic? Probably not. Ironically, though, investing in Ozempic, or rather in its manufacturer, Novo Nordisk (NYSE: NVO), hasn’t gone very well this year. Shares have fallen by 40% in 2025. Competition from Eli Lilly‘s similar drug, Zepbound, and from […]